BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

877 related articles for article (PubMed ID: 16604728)

  • 1. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
    Ruta J; Ptaszyński P; Maciejewski M; Chizyński K; Goch JH
    Przegl Lek; 2006; 63(12):1249-51. PubMed ID: 17642132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J; Ertl G
    Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone blockade in heart failure.
    Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction: from myocardial infarction to heart failure].
    Greco C; Castelli G; Crea F; Gavazzi A; Gensini GF; Scherillo M; Sinagra G
    G Ital Cardiol (Rome); 2012 Dec; 13(12):809-16. PubMed ID: 23196683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
    J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.